Leadership
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
With two late-stage lupus assets finishing recruitment and a newly acquired nephrology franchise running three concurrent Phase III programs, Biogen is making its most significant commitment yet to immunology beyond its legacy MS business.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.
Anat Cohen-Dayag explains how Compugen transformed from computational service provider to clinical-stage biotech by integrating AI with biology and structuring strategic pharma collaborations.
Entering 2026, Lupin is positioning itself for growth, with a keen focus on the expanding ophthalmology market.
Charles River’s CSO Julie Frearson outlines the FDA’s planned transition away from animal testing, changing attitudes to artificial intelligence, and the move to New Alternative Methods.
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
EY's Arda Ural joins In Vivo to discuss the long-awaited recovery in biotech IPOs, the evolving capital markets landscape and how tariffs and TrumpRx are reshaping biopharma supply chains.
Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
Launched in April 2025, Astellas’s Innovation Lab unites fragmented research units under Morten Sogaard to pursue focused indications, a dual-track R&D strategy and tailored partnerships that balance innovation, risk and collaboration.
Resmed’s CMO Carlos Nunez discusses the sleep giant’s continued push from medtech into healthtech and its efforts to fix what he calls a “broken pathway” to diagnosis and treatment for millions with undetected sleep apnea.
The Japanese pharma specialist has embarked on an ambitious journey to become a global specialty pharmaceutical company, driven by its first non-Japanese president at the helm.
Aviv Regev is betting AI-driven drug discovery can transform Genentech's pipeline, with early wins validating her computational biology approach to pharmaceutical R&D.
The culmination of the MedTech Innovator APAC awards program 2025 comes later this month when the top prizes are handed out at the grand final in Singapore. But all cohort companies benefit from the competition’s mentoring process, says awards organizer Fredrik Nyberg.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The billion-dollar startup has doubled headcount, released massive datasets and is advancing therapeutics, but the hard part lies ahead.